Pfizer is exiting its HIV-focused joint venture, ViiV Healthcare, while reshaping its portfolio around other therapeutic ...

Albert Bourla said Pfizer has discussed a fast-pass voucher with the White House during the JPMorgan Healthcare Conference.

Add Yahoo as a preferred source to see more of our stories on Google. The FDA has approved a label change to Pfizer's contraceptive injection The US Food and Drug Administration (FDA) has approved a ...

Guardant’s test analyzes circulating tumor DNA that is then used to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from treatment with the Braftovi combo therapy ...

Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. ・The company purchased Metsera in November for up to $10 billion to reignite its ...

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted a 2028 launch. CEO Albert Bourla explained the pharma's strategy at J.P.

CNBC spoke to executives from Eli Lilly, Novo Nordisk, Pfizer and other drugmakers at the annual JPMorgan Healthcare ...

The U.S. Food and Drug Administration (FDA) has approved a label change for Pfizer Inc.'s (NYSE: PFE) Depo-Provera contraceptive injection, adding a warning about the risk of meningioma, a type of ...

NEW YORK -- A course of pills developed by Pfizer can slash the risk of being hospitalized or dying from COVID-19 by 89% if taken within three days of developing symptoms, according to results ...

Pfizer/BioNTech has initiated its application to the US Food and Drug Administration for full FDA approval of its Covid-19 vaccine for people ages 16 and older, the companies said Friday. This is the ...